Yazar "Vicente, D." seçeneğine göre listele
Listeleniyor 1 - 3 / 3
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407(Elsevier Science Inc, 2021) Robinson, A. G.; Vicente, D.; Tafreshi, A.; Parra, H. Soto; Mazieres, J.; Cicin, I.; Medgyasszay, B.[Abstract Not Available]Öğe Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: Data from KEYNOTE-407(Oxford Univ Press, 2018) Mazieres, J.; Kowalski, D.; Luft, A.; Vicente, D.; Tafreshi, A.; Gumus, M.; Laktionov, K.[Abstract Not Available]Öğe Pembrolizumab (pembro) 1 chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407(Oxford Univ Press, 2019) Paz-Ares, L.; Vicente, D.; Tafreshi, A.; Robinson, A.; Soto Parra, H.; Mazieres, J.; Hermes, B.[Abstract Not Available]
